Lucie Carolle Kenmogne Selected Research

Androsterone

1/2017

Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lucie Carolle Kenmogne Research Topics

Disease

3	Prostatic Neoplasms (Prostate Cancer) 01/2017 - 09/2015
2	Neoplasms (Cancer) 01/2017 - 01/2015
1	Hyperplasia 05/2016

Drug/Important Bio-Agent (IBA)

3	AndrogensIBA 01/2017 - 09/2015
2	EnzymesIBA 01/2017 - 05/2016
2	Oxidoreductases (Dehydrogenase)IBA 01/2017 - 05/2016
1	RM-532-105IBA 01/2017
1	Androstenedione (4 Androstene 3,17 dione)IBA 01/2017
1	AndrosteroneIBA 01/2017
1	Dihydrotestosterone (Androstanolone)IBA 01/2017
1	SteroidsIBA 01/2017
1	Testosterone (Sustanon)FDA Link 01/2017
1	Hormones (Hormone)IBA 09/2015
1	Pharmaceutical PreparationsIBA 01/2015
1	Methylcellulose (BFL)IBA 01/2015

Therapy/Procedure

1	Subcutaneous Injections 01/2015